RedHill Biopharma, an Israeli biopharmaceutical company announced positive results in a clinical trial with RHB-103, an oral thin-film formulation of Rizatriptan for the treatment of acute migraine. According to the company, the trial, which was conducted in Canada, met its specified endpoints and FDA’s criteria. RedHill focuses primarily on development of late clinical-stage, patent protected, new formulations and combinations of existing drugs. It is developing RHB-103 with its Canadian co-development partner IntelGenx. The company is targeting a segment of the migraine market – namely the family of triptan migraine drugs – estimated at approximately $2 billion in 2011.